A polymeric micelle system with a hydrolysable segment for drug delivery

Area of Science:

• Polymer Chemistry
• Materials Science
• Drug Delivery Systems

Background:

• Development of advanced drug delivery systems is crucial for effective cancer therapy.
• Polymeric micelles offer a promising platform for encapsulating hydrophobic drugs.
• Stimuli-responsive systems enhance drug release control and reduce side effects.

Purpose of the Study:

• To synthesize and characterize a novel amphiphilic co-polymer for creating ultrasound-sensitive polymeric micelles.
• To evaluate the drug-loading and release capabilities of these micelles using doxorubicin (Dox).
• To investigate the degradation profile and responsiveness of the developed drug delivery system.

Main Methods:

• Synthesis of poly(ethylene oxide)-b-poly(N-isopropylacrylamide-co-2-hydroxyethyl methacrylate-lactate(n)) co-polymers.
• Optimization of polymer composition for a 48-hour in vitro degradation half-life at 40°C.
• Characterization of micelle core hydrophobicity using 1,6-Diphenyl-1,3,5-hexatriene (DPH).
• Encapsulation of doxorubicin (Dox) into optimized micelles (NIPAAm:HEMA-lactate3:PEO ratio 20:5:1).
• In vitro drug release studies triggered by low-frequency ultrasound at room and body temperatures.

Main Results:

• Polymeric micelles with a stable in vitro degradation half-life of approximately 48 hours at 40°C were successfully synthesized.
• The micelle cores demonstrated sufficient hydrophobicity to encapsulate the fluorescent probe DPH and the anti-cancer drug doxorubicin (Dox).
• Ultrasound application triggered the release of Dox, with approximately 2% release at room temperature and 4% at body temperature.
• The encapsulated Dox was retained within the micelles when ultrasound application ceased, indicating controlled release.

Conclusions:

• A novel ultrasound-triggered polymeric micelle system for doxorubicin delivery was successfully developed.
• The system exhibits controlled drug release characteristics responsive to ultrasound stimuli.
• This technology holds potential for targeted anti-cancer drug delivery, improving therapeutic efficacy and reducing systemic toxicity.